Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.

Launched by TAKEDA · Oct 9, 2008

Keywords

ClinConnect Summary

Type 2 diabetes increases the risk of coronary heart disease at least by two to three fold compared with non-diabetic subjects. Moreover, prospective studies have shown a significant correlation between several glycemic confounders and morbidity from coronary heart disease even in patients without diabetes mellitus. In patients with previously diagnosed coronary heart disease, impaired glucose tolerance was found in 30 to 67 %. The cardiovascular risk of patients with insulin resistance, with or without glucose intolerance has become more and more apparent within recent years and quantitati...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Stable coronary artery disease with planned percutaneous coronary intervention with stent implantation.
• • Type II-diabetics and/or an IRIS II score greater than or equal to 50 (measure for the identification of patients with insulin resistance and increased vascular risk).
• • Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
• Exclusion Criteria:
• • A planned percutaneous coronary intervention with stent implantation less than 15 days after the screening visit.
• • Planned multi-vessel intervention.
• • Use of systemic corticosteroids within the last 3 months prior to screening visit.
• • Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures.
• • History of severe or multiple allergies.
• • Treatment with any other investigational drug within 3 months before trial entry or earlier participation in the present study.
• • Have had more than one unexplained episode of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to screening visit.
• • Progressive fatal disease.
• • History of drug or alcohol abuse within the last 10 years.
• • A history of significant cardiovascular (New York Health Association stage II - IV), respiratory, gastrointestinal, hepatic (alanine aminotransferase greater than 2.5 times the normal reference range), renal (creatinine greater than 1.2 mg/dL in women and greater than 1.5 in men and/or glomerular filtration rate less than 45), neurological, psychiatric and/or hematological disease as judged by the Investigator.
• • Pre-treatment with peroxisome proliferator-activated receptor (gamma) agonists within the 3 months prior to screening.
• • If insulin therapy applicable: initiation of insulin therapy within the last 3 months.
• • If statin therapy applicable: change of medication within the last 4 weeks.
• • Myocardial infarction within 3 months prior to screening visit.
• • Blood donation within last 30 days.